BH3 Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PTC Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.20 |
| 52 Week High | US$43.40 |
| 52 Week Low | US$19.40 |
| Beta | 0.63 |
| 11 Month Change | 17.39% |
| 3 Month Change | 39.35% |
| 1 Year Change | 122.68% |
| 33 Year Change | 35.85% |
| 5 Year Change | -2.26% |
| Change since IPO | 223.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| BH3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.4% | -1.1% | 1.1% |
| 1Y | 122.7% | -18.8% | 7.2% |
Return vs Industry: BH3 exceeded the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: BH3 exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| BH3 volatility | |
|---|---|
| BH3 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BH3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BH3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,022 | Matt Klein | www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
PTC Therapeutics, Inc. Fundamentals Summary
| BH3 fundamental statistics | |
|---|---|
| Market cap | €3.36b |
| Earnings (TTM) | -€428.55m |
| Revenue (TTM) | €851.67m |
3.9x
P/S Ratio-7.8x
P/E RatioIs BH3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BH3 income statement (TTM) | |
|---|---|
| Revenue | US$900.66m |
| Cost of Revenue | US$601.30m |
| Gross Profit | US$299.37m |
| Other Expenses | US$752.57m |
| Earnings | -US$453.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.88 |
| Gross Margin | 33.24% |
| Net Profit Margin | -50.32% |
| Debt/Equity Ratio | -224.5% |
How did BH3 perform over the long term?
See historical performance and comparison